WHAT IS CLAIMED IS:

1. A composition comprising:

(a) 10-45 mg/ml crosslinked glycosaminoglycan hydrogel,

(b) 20%-50% free, non-crosslinked glycosaminoglycan by weight of the crosslinked glycosaminoglycan hydrogel, and

(c) 10-50 mg/ml biodegradable poly (alpha-hydroxy acid) polymer, wherein the biodegradable poly (alpha-hydroxy acid) polymer is not crosslinked to the glycosaminoglycan hydrogel or the free, non-crosslinked glycosaminoglycan.

2. A composition prepared by a process, comprising:

(a) crosslinking a glycosaminoglycan in the presence of 2% - 4% v/v NaOH, thereby obtaining a crosslinked glycosaminoglycan hydrogel;

(b) filtering the crosslinked glycosaminoglycan hydrogel using a 60-90 micron filter;

(c) adding to the filtered crosslinked glycosaminoglycan hydrogel 20%-50% free, non-crosslinked glycosaminoglycan by weight of the crosslinked glycosaminoglycan hydrogel; and

(d) adding to the composition from (c) 10-50 mg/ml biodegradable poly (alpha-hydroxy acid) polymer under vacuum conditions, wherein the biodegradable poly (alpha-hydroxy acid) polymer is not crosslinked to the glycosaminoglycan hydrogel.

3. The composition of claim 2, the process further comprising swelling the crosslinked glycosaminoglycan hydrogel under vacuum conditions between (a) and (b); precipitating and washing the filtered crosslinked glycosaminoglycan hydrogel from (b) using ethanol; and/or sterilizing the composition after (d).

4. The composition of any one of claims 1-3, wherein the composition comprises (i) 15-20 mg/ml, 15-25 mg/ml, 15-30 mg/ml, 15-35 mg/ml, or 15-40 mg/ml crosslinked glycosaminoglycan hydrogel, and/or (ii) 10-15 mg/ml, 10-20 mg/ml, 10-25 mg/ml, 10-30 mg/ml, 10-35 mg/ml, 10-40 mg/ml or 10-50 mg/ml biodegradable poly (alpha-hydroxy acid) polymer.

5. The composition of any one of claims 1-4, wherein the composition comprises 20%-30%, 20%-35%, 20%-40% or 20%-45% free, non-crosslinked glycosaminoglycan by weight of the crosslinked glycosaminoglycan hydrogel.

6. The composition of any one of claims 1-5, wherein the crosslinked glycosaminoglycan hydrogel comprises crosslinked hyaluronic acid (HA), crosslinked heparan sulfate (HS), crosslinked heparin (HEP), crosslinked chondroitin sulfate (CS), crosslinked dermatan sulfate (DS), or crosslinked keratan sulfate (KS), or a combination thereof.

7. The composition of any one of claims 1-6, wherein the free glycosaminoglycan comprises hyaluronic acid (HA), heparan sulfate (HS), heparin (HEP), chondroitin sulfate (CS), dermatan sulfate (DS), or keratan sulfate (KS), or a combination thereof.

8. The composition of any one of claims 1-7, wherein the biodegradable poly (alpha-hydroxy acid) polymer comprises poly-L-lactic acid (PLLA), poly-D-lactic acid (PLDA), polyglycolic acid (PLGA) or poly (diol) citrate (PDC) or a combination thereof.

9. The composition of any one of claims 1-8, wherein the crosslinked glycosaminoglycan is crosslinked by one or more polyfunctional crosslinking agent(s) selected from the group consisting of divinyl sulfone, multiepoxides, and diepoxides or selected from the group consisting of 1,4-butanediol diglycidyl ether (BDDE), 1,2-ethanediol diglycidyl ether (EDDE) and diepoxyoctane.

10. The composition of any one of claims 1-8, wherein the crosslinked glycosaminoglycan is crosslinked by (i) a non-carbohydrate-based di- or multinucleofile crosslinker or (ii) a carbohydrate based di- or multinucleofile crosslinker, wherein the non-carbohydrate-based di- or multinucleofile crosslinker is optionally selected from hexamethylenediamine (HMDA) and diaminotrehalose (DATH).

11. The composition of any one of claims 1-10, wherein the composition is an injectable composition.

12. A method for improving skin quality in a subject in need of such treatment comprising administering the subject the composition of any one of claims 1-10.

13. A method for preparing a composition, comprising:

(a) crosslinking a glycosaminoglycan in the presence of 2% - 4% v/v NaOH, thereby obtaining a crosslinked glycosaminoglycan hydrogel;

(b) filtering the crosslinked glycosaminoglycan hydrogel using a 60-90 micron filter;

(c) adding to the filtered crosslinked glycosaminoglycan hydrogel 20%-50% free glycosaminoglycan by weight of the composition; and

(d) adding to the composition in step (c) 10-50 mg/ml biodegradable poly (alpha-hydroxy acid) polymer under vacuum conditions, wherein the biodegradable poly (alpha-hydroxy acid) polymer is not crosslinked to the glycosaminoglycan hydrogel.

14. The method of claim 13, further comprising swelling the crosslinked glycosaminoglycan hydrogel under vacuum conditions between (a) and (b, precipitating and washing the filtered crosslinked glycosaminoglycan hydrogel from (b) using ethanol, and/or sterilizing the composition after (d).

15. The method of claim 13 or 14, wherein the composition comprises (i) 15-20 mg/ml, 15-25 mg/ml, 15-30 mg/ml, 15-35 mg/ml, or 15-40 mg/ml crosslinked glycosaminoglycan hydrogel, and/or (ii) 10-15 mg/ml, 10-15 mg/ml, 10-20 mg/ml, 10-25 mg/ml, 10-30 mg/ml, 10-35 mg/ml, 10-40 mg/ml or 10-45 mg/ml biodegradable poly (alpha-hydroxy acid) polymer.

16. The method of any one of claims 13-15, wherein the composition comprises 20%-30%, 20%-35%, 20%-40% or 20%-45% free glycosaminoglycan by weight of the composition.

17. The method of any one of claims 13-16, wherein (i) the crosslinked glycosaminoglycan hydrogel comprises crosslinked hyaluronic acid (HA), crosslinked heparan sulfate (HS), crosslinked heparin (HEP), crosslinked chondroitin sulfate (CS), crosslinked dermatan sulfate (DS), or crosslinked keratan sulfate (KS), or a combination thereof; (ii) the free glycosaminoglycan comprises hyaluronic acid (HA), heparan sulfate (HS), heparin (HEP),

chondroitin sulfate (CS), dermatan sulfate (DS), or keratan sulfate (KS), or a combination thereof; and/or (iii) the biodegradable poly (alpha-hydroxy acid) polymer comprises poly-L-lactic acid (PLLA), poly-D-lactic acid (PLDA), polyglycolic acid (PLGA) or poly (diol) citrate (PDC) or a combination thereof.

18. The method of any one of claims 13-17, wherein the crosslinked glycosaminoglycan is crosslinked by one or more polyfunctional crosslinking agent(s) selected from the group consisting of divinyl sulfone, multiepoxides and diepoxides or selected from the group consisting of 1,4-butanediol diglycidyl ether (BDDE), 1,2-ethanediol diglycidyl ether (EDDE) and diepoxyoctane.

19. The method of any one of claims 13-17, wherein the crosslinked glycosaminoglycan is crosslinked by (i) a non-carbohydrate-based di- or multinucleofile crosslinker or (ii) a carbohydrate based di- or multinucleofile crosslinker, wherein the non-carbohydrate-based di- or multinucleofile crosslinker is optionally selected from hexamethylenediamine (HMDA)and diaminotrehalose (DATH).

20. The method of any one of claims 13-19, further comprising formulating the composition as an injectable composition.